Already a member? Sign in
Montelukast is used for prophylaxis and chronic treatment of asthma; relief of symptoms of seasonal allergic rhinitis and perennial allergic rhinitis; prevention of exercise-induced bronchospasm.
Read more...
| Purpose | # of patients |
# of patients with evaluations
Efficacy
|
Major | Moderate | Slight | None | Can’t tell |
|---|---|---|---|---|---|---|---|
| Asthma | 139 | 36 |
|
|
|
|
|
| Allergies | 131 | 21 |
|
|
|
|
|
| Other | 43 | 9 |
|
|
|
||
| Seasonal Allergy | 30 | 2 |
|
|
|||
| Perennial Allergy | 30 | 3 |
|
|
|||
| Asthma | 27 | 6 |
|
|
|
See all 368 patients currently taking montelukast
Mouse over the table for more information
Commonly reported side effects, conditions, and hospitalizations associated with montelukast
| Difficulty falling asleep | 2 | |
|---|---|---|
| Tiredness | 2 | |
| Cough | 2 | |
| Personality changes due to medication | 1 | |
| Allergies | 1 | |
| Sluggishness | 1 | |
| See all 10 reported side effects ▼ | ||
Frequently reported dosages based on patients currently taking montelukast. See all 15 dosages ►
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Expense | 18 | ||
| Other | 16 | ||
| Did not seem to work | 13 | ||
| Doctor's advice | 11 | ||
| Side effects too severe | 9 | ||
| Course of treatment ended | 8 | ||
| Change in health plan coverage | 6 | ||
| Personal research | 4 | ||
| Not indicated | 1 |
Adherence
Taking treatment as prescribed
Adherence of montelukast
Always |
59 | 83% |
|
|---|---|---|---|
Usually |
11 | 15% |
|
Sometimes |
0 | 0% |
|
Never |
1 | 1% |
|
Burden
Difficulty being on treatment
Burden of montelukast
Very |
1 | 1% |
|
|---|---|---|---|
Somewhat |
3 | 4% |
|
A little |
5 | 7% |
|
Not at all |
62 | 87% |
|
Cost
Paid out of pocket
Cost of montelukast
$200+ |
0 | 0% |
|
|---|---|---|---|
$100-199 |
1 | 3% |
|
$50-99 |
6 | 15% |
|
$25-49 |
12 | 31% |
|
< $25 |
20 | 51% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on February 10, 2012.